Table 1 Summary of study population characteristics at baseline (mITT population)
|  | All patients (N = 8509) |
|---|---|
Age, years, mean (SD) | 64.7 (7.6) |
Male, n (%) | 5081 (59.7) |
Treatment arm, n (%) | |
 BGF 320/18/9.6 µg | 2137 (25.1) |
 BGF 160/18/9.6 µg | 2121 (24.9) |
 GFF 18/9.6 µg | 2120 (24.9) |
 BFF 320/9.6 µg | 2131 (25.0) |
ICS use, n (%) | 6846 (80.5) |
Number of moderate or severe exacerbations in last year, median (range) | 2 (0–12) |
 1, n (%) | 3699 (43.5) |
  ≥ 2, n (%) | 4810 (56.5) |
Blood eosinophil count, mean × 109/L (SD) | 196.4 (132.8) |
Post-bronchodilator FEV1% predicted, mean % (SD) | 43.4 (10.3) |